Values First Advisors Inc. Has $584,000 Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Values First Advisors Inc. lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 11.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,205 shares of the company’s stock after acquiring an additional 6,140 shares during the period. Values First Advisors Inc.’s holdings in Recursion Pharmaceuticals were worth $584,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of RXRX. Swiss National Bank increased its stake in Recursion Pharmaceuticals by 7.6% during the 1st quarter. Swiss National Bank now owns 94,300 shares of the company’s stock worth $675,000 after purchasing an additional 6,700 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Recursion Pharmaceuticals by 1.7% during the 1st quarter. Bank of New York Mellon Corp now owns 373,700 shares of the company’s stock worth $2,676,000 after acquiring an additional 6,294 shares in the last quarter. MetLife Investment Management LLC grew its stake in shares of Recursion Pharmaceuticals by 55.4% during the 1st quarter. MetLife Investment Management LLC now owns 64,035 shares of the company’s stock worth $458,000 after acquiring an additional 22,833 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Recursion Pharmaceuticals by 4.0% during the 1st quarter. Rhumbline Advisers now owns 123,892 shares of the company’s stock worth $887,000 after acquiring an additional 4,818 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 8.1% in the 1st quarter. Vanguard Group Inc. now owns 6,611,377 shares of the company’s stock valued at $47,338,000 after buying an additional 497,504 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Needham & Company LLC increased their price objective on Recursion Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. TD Cowen began coverage on Recursion Pharmaceuticals in a report on Friday, January 26th. They issued a “market perform” rating for the company. Finally, KeyCorp raised their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $12.75.

Insider Buying and Selling

In related news, insider Shafique Virani sold 18,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $10.93, for a total value of $196,740.00. Following the transaction, the insider now directly owns 136,748 shares of the company’s stock, valued at $1,494,655.64. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Recursion Pharmaceuticals news, insider Shafique Virani sold 18,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $10.93, for a total value of $196,740.00. Following the transaction, the insider now directly owns 136,748 shares of the company’s stock, valued at $1,494,655.64. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Tina Marriott sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $10.75, for a total value of $86,000.00. Following the completion of the transaction, the chief operating officer now directly owns 639,982 shares in the company, valued at $6,879,806.50. The disclosure for this sale can be found here. Insiders have sold a total of 353,107 shares of company stock valued at $3,856,834 over the last ninety days. 19.96% of the stock is owned by company insiders.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock traded down $0.20 during mid-day trading on Thursday, hitting $9.97. 5,181,308 shares of the company’s stock traded hands, compared to its average volume of 7,178,251. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.54 and a fifty-two week high of $16.75. The stock has a market cap of $2.34 billion, a price-to-earnings ratio of -6.43 and a beta of 0.83. The firm has a 50 day simple moving average of $11.16 and a two-hundred day simple moving average of $9.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The company had revenue of $10.89 million during the quarter, compared to the consensus estimate of $12.37 million. On average, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.